Key result
Higher HbA1c/HDL-C ratio linked to ~7% greater heart failure risk per unit increase.
Why the study?
Heart failure remains a leading cause of morbidity and mortality worldwide, and the specific relationship between the novel HbA1c/HDL-C ratio and HF risk remains underexplored.
Is the HbA1c/HDL-C ratio associated with the risk of heart failure in adults?
Cross-Sectional (n=49,506)
Yes
Is the HbA1c/HDL-C ratio associated with the risk of heart failure in adults?
The HbA1c/HDL-C ratio demonstrates a nonlinear positive association with heart failure risk, offering better predictive power than either biomarker alone.
Answers are grounded in this paper and cite their sources.
HbA1c/HDL-C ratio was associated with HF; cross-sectional data leave open its incremental prognostic value.
Background Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. The HbA1c/HDL-C ratio, a novel composite biomarker reflecting glycemic control and lipid metabolism, may be associated with HF risk, but its specific relationship remains underexplored. This study aimed to investigate the association between the HbA1c/HDL-C ratio and HF. Methods We utilized samples from two sources: 1,360 inpatients from a cardiology department in 2020 and 101,316 participants from the National Health and Nutrition Examination Survey ( N HANES) 1999–2018. Multivariate logistic regression, subgroup analyses, restricted cubic spline (RCS) regression, and receiver-operating characteristic (ROC) curve analysis were employed to examine the relationship. Results In an analysis of the NHANES sample including 48,922 participants, 1,598 individuals were identified as having HF, corresponding to a prevalence of 3.27%. In a separate clinical sample of 584 participants, 132 had HF, yielding an overall prevalence of 22.60%. After full adjustment, the HbA1c/HDL-C ratio demonstrated a consistent positive association with HF risk in both the NHANES sample (OR =1.07, 95% CI: 1.01–1.14; P = 0.033) and the clinical sample (OR = 1.15, 95% CI: 1.01–1.30; P = 0.029). Furthermore, a nonlinear relationship between the HbA1c/HDL-C ratio and HF risk was observed in both populations, with an inflection point identified at 6.21. Below this threshold (HbA1c/HDL-C < 6.21), the adjusted OR was 1.22 (95% CI: 1.09–1.37; P = 0.001) in the NHANES sample and 1.65 (95% CI: 1.20–2.28; P = 0.002) in the clinical sample. Above the inflection point (HbA1c/HDL-C ≥ 6.21), the association attenuated and became statistically nonsignificant. The ROC curve analysis also confirmed that the HbA1c/HDL-C ratio combination had more robust predictive power for heart failure than HbA1c and HDL-C alone ( P < 0.05). Conclusion This study found a nonlinear positive association between the HbA1c/HDL-C ratio and the risk of HF, identifying key threshold values.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cross-sectional in Heart failure (n=49,506). HbA1c/HDL-C ratio vs. Lower HbA1c/HDL-C ratio was evaluated on Heart failure (OR 1.07, 95% CI 1.01-1.14, p=0.033). An elevated HbA1c/HDL-C ratio was nonlinearly associated with an increased risk of heart failure, demonstrating an adjusted OR of 1.07 per unit increase in the NHANES cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: